CN116463362A - Preparation method of cell division inhibitor - Google Patents
Preparation method of cell division inhibitor Download PDFInfo
- Publication number
- CN116463362A CN116463362A CN202310708460.9A CN202310708460A CN116463362A CN 116463362 A CN116463362 A CN 116463362A CN 202310708460 A CN202310708460 A CN 202310708460A CN 116463362 A CN116463362 A CN 116463362A
- Authority
- CN
- China
- Prior art keywords
- concentration
- marc
- liquid
- bacterial
- viob
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000032823 cell division Effects 0.000 title claims abstract description 19
- 239000003112 inhibitor Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 239000000047 product Substances 0.000 claims abstract description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000003960 Ligases Human genes 0.000 claims abstract description 11
- 108090000364 Ligases Proteins 0.000 claims abstract description 11
- 239000012043 crude product Substances 0.000 claims abstract description 10
- 239000012074 organic phase Substances 0.000 claims abstract description 8
- 239000012295 chemical reaction liquid Substances 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 4
- 239000000839 emulsion Substances 0.000 claims abstract description 4
- 238000006911 enzymatic reaction Methods 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 230000001105 regulatory effect Effects 0.000 claims abstract description 4
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 4
- 238000007781 pre-processing Methods 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims description 93
- 230000001580 bacterial effect Effects 0.000 claims description 77
- 239000000243 solution Substances 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 239000012634 fragment Substances 0.000 claims description 36
- 239000002609 medium Substances 0.000 claims description 34
- 239000013604 expression vector Substances 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 27
- 239000012160 loading buffer Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 239000000725 suspension Substances 0.000 claims description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 18
- 229930027917 kanamycin Natural products 0.000 claims description 18
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 18
- 229960000318 kanamycin Drugs 0.000 claims description 18
- 229930182823 kanamycin A Natural products 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 18
- 239000006166 lysate Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 13
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 12
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 12
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000010367 cloning Methods 0.000 claims description 9
- 230000001376 precipitating effect Effects 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229940010514 ammonium ferrous sulfate Drugs 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 239000011790 ferrous sulphate Substances 0.000 claims description 6
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 6
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 6
- 101150002431 vioB gene Proteins 0.000 claims description 5
- 230000010355 oscillation Effects 0.000 claims description 4
- 239000003531 protein hydrolysate Substances 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 239000012880 LB liquid culture medium Substances 0.000 claims description 3
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 3
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 239000011550 stock solution Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 9
- 239000000758 substrate Substances 0.000 abstract description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 6
- 229960002885 histidine Drugs 0.000 abstract description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 13
- 108090000315 Protein Kinase C Proteins 0.000 description 13
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 7
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 231100000481 chemical toxicant Toxicity 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- TUOXXENDICUNMW-UHFFFAOYSA-N didemnidine A Chemical compound C1=CC=C2C(C(=O)C(=O)NCCCNCCCCN)=CNC2=C1 TUOXXENDICUNMW-UHFFFAOYSA-N 0.000 description 2
- 238000003674 kinase activity assay Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 241000251557 Ascidiacea Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
Abstract
The invention discloses a preparation method of a cell division inhibitor, which comprises the following steps: step one, synthesizing key synthetase and constructing a carrier; step two, expressing and preprocessing key synthetase; step three, building an enzymatic reaction system; and step four, regulating the pH value of the reaction liquid obtained in the step three to be 1, adding ethyl acetate 1L into the reaction liquid to extract for at least three times, filtering an emulsion layer by using diatomite, separating the solution, combining organic phases, drying, concentrating under reduced pressure to obtain a crude product, purifying the crude product by using silica gel column chromatography, and eluting to obtain an orange-red product to obtain the cell division inhibitor. The invention has the following beneficial effects: 1. the reaction steps are few; 2. l-tryptophan and L-histidine with low cost and good biological affinity are used as substrates, so that the atom utilization rate is improved, and chemical pollution and possibly introduced toxic and side effects are reduced; 3. realizes the synthesis of gram-grade products, saves the cost of the subsequent preparation of the medicines and reduces the price of the medicines.
Description
Technical Field
The invention belongs to the field of drug synthesis, and particularly relates to a preparation method of a cell division inhibitor.
Background
In recent years, dimeric amino acid active natural products have received widespread attention for pharmaceutical use due to their generally good biological activity. The tryptophan-histidine heterodimer represented by DDM-A (Didemnidine A) from natural sources shows outstanding activity in inhibiting cell division G2 phase check points and the like, and meanwhile, the tryptophan-histidine heterodimer also has certain topoisomerase I and protein kinase C inhibition effects, and the biological activity makes the tryptophan-histidine heterodimer an ideal molecular model and a patent medicine precursor of medicines such as anticancer medicines, antimalarial medicines and the like. thestructuralformulaofDDM-Aisasfollows:
。
currently,DDM-aofnaturaloriginismainlyderivedfromthechordaeintheocean,ascidians,themainfunctionofDDM-ainnaturebeingtoalertanddefendpotentialpredators. inrecentyears,theyieldofnaturalsourcesofDDM-Ahasbeenextremelylimitedduetoexcessivedevelopmentofmarineresourcesandenvironmentalpollution.
DDM-Aanditsderivativesarepreparedbythecurrentcommonchemicalsynthesismethod,andthesyntheticrouteisasfollows:
however, the technical scheme has the following defects: 1. the preparation route is longer, the method is a multi-step reaction, the method is complex and tedious, and the separation and purification are required to be carried out independently after each step of reaction is finished; 2. the reaction raw materials and the reaction byproducts are often toxic, so that chemical pollution is easy to cause, and the biological safety is doubtful; 3. theefficiencyofsynthesizingDDM-Aisnothigh,theoverallrecoveryyieldisgenerallylowerthan50%,andthereactionscaleisusuallyintheorderofhundredmilligrams,sothatmassproductioncannotberealized.
Disclosure of Invention
The invention aims to: thepresentinventionhasbeenmadeinviewoftheabove-mentionedproblemsoccurringinthepriorart,anditisanobjectofthepresentinventiontodiscloseamethodforpreparingacelldivisioninhibitor,whichiscapableofdirectlypreparingDDM-aasacelldivisioninhibitorbyaone-pottwo-stepmethod.
The technical scheme is as follows: a preparation method of a cell division inhibitor comprises the following specific steps:
step one: synthesis and vector construction of key synthetases
(11) Synthesizing LAAD gene fragments, vioB gene fragments and MarC gene fragments for expressing key synthetase, wherein:
the amino acid sequence of the LAAD gene fragment is shown as SEQ ID NO. 1;
the amino acid sequence of the VioB gene fragment is shown as SEQ ID NO. 2;
the amino acid sequence of the MarC gene fragment is shown as SEQ ID NO. 3;
(12) Cloning the LAAD gene fragment into a pET28a (+) vector by using a Gibson splicing cloning technology to obtain an expression vector pET28a (+) -LAAD, and cloning the VioB gene fragment and the MarC gene fragment into a pET26b vector to obtain an expression vector pET26b-VioB and an expression vector pET26b-MarC, wherein:
the LAAD gene fragment, the VioB gene fragment and the MarC gene fragment are positioned between NdeI and HindIII restriction enzyme sites;
(13) Respectively converting the constructed expression vectors pET28a (+) -LAAD, pET26b-VioB and pET26b-MarC into competent cells BL21 (DE 3) to obtain strain solutions, and respectively storing at-80 ℃;
step two: expression and pretreatment of key synthetases
(21) Preparation of LAAD protein crude lysate
(211) Adding 10 uL of pET28a (+) -LAAD strain solution into 5 mL of LB liquid culture medium, and shaking overnight at 37 ℃ and 200rpm for culture to obtain pET28a (+) -LAAD seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(212) Adding the pET28a (+) -LAAD seed solution obtained in the step (211) into a test container containing 1L of LB liquid medium, and then shake culturing at 37 ℃ and 200rpm in a shaking table until the concentration OD of LAAD expression vector in the bacterial liquid is reached 600 Until 1.1-1.3, the test vessel was then removed and placed in an ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(213) Adding a proper amount of IPTG into the bacterial liquid treated in the step (212) to ensure that the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table to perform induction culture at 18 ℃ and 200rpm for 16 h;
(214) Pouring the bacterial liquid induced in the step (213) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 5 mM imidazole, 10% v/v glycerol, the balance being water;
(215) Crushing the bacterial body weight suspension obtained in the step (214) by using an ultrasonic crusher to obtain crushed bacterial liquid, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(216) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain LAAD protein crude lysate;
(22) Preparation of VioB protein crude lysate
(221) Adding 10 uL of pET26b-VioB strain solution into 5 mL of LB liquid medium, and performing shake culture at 37 ℃ and 200rpm overnight to obtain pET26b-VioB seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(222) Adding the pET26b-VioB seed solution obtained in the step (221) into a test container containing 1L of LB liquid medium, and shake culturing in a shaking table at 37 ℃ and 200rpm until the concentration OD of the VioB expression vector is reached 600 Until =0.7-0.9, the test vessel was then placed in an ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(223) Adding proper amounts of ammonium ferrous sulfate, 5-aminolevulinic acid and IPTG into the bacterial liquid treated in the step (222) respectively, so that the concentration of the ammonium ferrous sulfate in the bacterial liquid is 40 uM, the concentration of the 5-aminolevulinic acid in the bacterial liquid is 0.25 mM, and the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table for induced culture at 18 ℃ and 200rpm for 16 h;
(224) Pouring the bacterial liquid induced in the step (223) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 10% v/v glycerol, the balance being water;
(225) Crushing the bacterial body weight suspension obtained in the step (224) by using a ultrasonic crusher, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(226) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain crude VioB protein lysate.
(23) Preparation of MarC protein crude lysate
(231) Adding 10 uL of pET26b-MarC strain solution into 5 mL of LB liquid medium, and performing shake culture at 37 ℃ and 200rpm overnight to obtain pET26b-MarC seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(232) Adding the pET26b-MarC seed solution obtained in the step (231) into a test container containing 1L of LB liquid medium, and shake culturing in a shaking table at 37 ℃ and 200rpm until the concentration OD of the MarC expression vector is reached 600 Until =0.9-1.1, the test vessel was then removed and placed in an ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(233) Respectively adding ferrous ammonium sulfate, 5-aminolevulinic acid and IPTG into the bacterial liquid treated in the step (232) to ensure that the concentration of the ferrous ammonium sulfate in the bacterial liquid is 40 uM, the concentration of the 5-aminolevulinic acid in the bacterial liquid is 0.25 mM, and the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table for induced culture at 18 ℃ and 200rpm for 16 h;
(234) Pouring the bacterial liquid induced in the step (234) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 10% v/v glycerol, the balance being water;
(235) Crushing the bacterial body heavy suspension by using an ultrasonic crusher, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(236) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain MarC protein crude lysate;
step three: construction of enzymatic reaction System
(31) The following substances were added to the reaction vessel separately:
,
wherein:
the NaH is 2 PO 4 -Na 2 HPO 4 The concentration of the buffer solution is 1M, and the pH value is 8.0;
said (NH) 4 ) 2 SO 4 The concentration of the stock solution was 2M;
(32) After uniform mixing, carrying out oscillation reaction for 6-8h, wherein the reaction vessel is kept in an open state (namely, the oxygen concentration at the upper part of the reaction vessel is the same as the oxygen concentration in the air) in the whole process of the oscillation reaction;
(33) Adding 600 mL of MarC protein crude lysate prepared in the step (23), 2.1g of alpha-ketoglutaric acid, 1.32 g of ascorbic acid and a proper amount of ferrous sulfate into a reaction vessel respectively, so that the concentration of the ferrous sulfate in bacterial liquid is 0.1 mM, mixing uniformly, and continuing to shake and react for 2 hours to obtain a reaction liquid;
step four: separation and purification of the product
And (3) regulating the pH value of the reaction solution obtained in the step (III) to be 1 by using 1N dilute hydrochloric acid, adding ethyl acetate 1L to the reaction solution for extraction for at least three times, filtering an emulsion layer by using diatomite, separating the solution, combining organic phases, drying the organic phases by using anhydrous sodium sulfate, concentrating the organic phases under reduced pressure to obtain a crude product, purifying the crude product by using silica gel column chromatography, and eluting the crude product under the condition of DCM/MeOH=20:1 to obtain an orange-red product, thus obtaining the cell division inhibitor.
The beneficial effects are that: the invention has the following beneficial effects:
1. the reaction steps are few, namely, on the basis of the research results of the synthesis biology, a 2-step synthesis method taking key enzymes LAAD, vioB and MarC as catalytic conditions is developed;
2. the cheap and good biological affinity L-tryptophan and L-histidine are used as substrates, so that the participation of toxic chemicals as substrates in the existing method is avoided, the atomic utilization rate is improved, the chemical pollution is reduced, and the possibly introduced toxic and side effects are reduced;
3. in a reaction system as small as possible, the synthesis of gram-grade products is realized, the recovery yield is higher than that of the existing chemical synthesis means, the cost of the subsequent preparation of the medicines is saved, and the medicine price is reduced.
Drawings
FIG. 1 is a vector map of the expression vector pET28a (+) -LAAD.
FIG. 2 is a vector map of the expression vector pET26 b-VioB.
FIG. 3 is a vector map of the expression vector pET26 b-MarC.
FIG. 4 is an HPLC plot of the product prepared in example 1.
FIG. 5 is a diagram of the product of example 1 1 H NMR spectrum.
FIG. 6 is a diagram of the product of example 1 13 C NMR spectrum.
FIG. 7 is a single crystal growth chart under a microscope of the product prepared in example 1.
Detailed Description
The following detailed description of specific embodiments of the invention.
The endpoints and any values of the ranges disclosed herein are not limited to the precise range or value, and are understood to encompass values approaching those ranges or values. For numerical ranges, one or more new numerical ranges may be found between the endpoints of each range, between the endpoint of each range and the individual point value, and between the individual point value, in combination with each other, and are to be considered as specifically disclosed herein.
1. Aiming at the problem of longer route of the current chemical synthesis method, a 2-step synthesis method taking key enzymes LAAD, vioB and MarC as catalytic conditions is developed on the basis of the research results of the synthesis biology, and the specific reaction steps are as follows:
2. the method takes the L-tryptophan and the L-histidine with low cost and good biological affinity as the substrates, avoids the participation of toxic chemicals as the substrates in the existing method, improves the atomic utilization rate, reduces the chemical pollution and the possibly introduced toxic and side effects.
3. The invention also needs to solve the problem of low yield caused by the increase of synthesis steps in the prior art route, realize the synthesis of gram-grade products in a reaction system as small as possible, and have recovery yield higher than that of the prior chemical synthesis means. So as to save the cost of the subsequent preparation of the medicines and reduce the price of the medicines.
Example 1
A preparation method of a cell division inhibitor comprises the following specific steps:
step one: synthesis and vector construction of key synthetases
(11) Synthesizing LAAD gene fragments, vioB gene fragments and MarC gene fragments for expressing key synthetase, wherein:
the amino acid sequence of the LAAD gene fragment is shown as SEQ ID NO. 1;
the amino acid sequence of the VioB gene fragment is shown as SEQ ID NO. 2;
the amino acid sequence of the MarC gene fragment is shown as SEQ ID NO. 3;
(12) Cloning the LAAD gene fragment into a pET28a (+) vector by using a Gibson splicing cloning technology to obtain an expression vector pET28a (+) -LAAD, and cloning the VioB gene fragment and the MarC gene fragment into a pET26b vector to obtain an expression vector pET26b-VioB and an expression vector pET26b-MarC respectively, wherein the specific steps are shown in figures 1-3, and the specific steps are as follows:
the LAAD gene fragment, the VioB gene fragment and the MarC gene fragment are positioned between NdeI and HindIII restriction enzyme sites;
(13) Respectively converting the constructed expression vectors pET28a (+) -LAAD, pET26b-VioB and pET26b-MarC into competent cells BL21 (DE 3) to obtain strain solutions, and respectively storing at-80 ℃;
step two: expression and pretreatment of key synthetases
(21) Preparation of LAAD protein crude lysate
(211) Adding 10 uL of pET28a (+) -LAAD strain solution into 5 mL of LB liquid culture medium, and shaking overnight at 37 ℃ and 200rpm for culture to obtain pET28a (+) -LAAD seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(212) Adding the pET28a (+) -LAAD seed solution obtained in the step (211) into a test container containing 1L of LB liquid medium, and then shake culturing at 37 ℃ and 200rpm in a shaking table until the concentration OD of LAAD expression vector in the bacterial liquid is reached 600 Stop incubation at=1.2, then take out the test vessel and place in ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(213) Adding a proper amount of IPTG into the bacterial liquid treated in the step (212) to ensure that the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table to perform induction culture at 18 ℃ and 200rpm for 16 h;
(214) Pouring the bacterial liquid induced in the step (213) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 5 mM imidazole, 10% v/v glycerol, the balance being water;
(215) Crushing the bacterial body weight suspension obtained in the step (214) by using an ultrasonic crusher to obtain crushed bacterial liquid, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(216) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain LAAD protein crude lysate;
(22) Preparation of VioB protein crude lysate
(221) Adding 10 uL of pET26b-VioB strain solution into 5 mL of LB liquid medium, and performing shake culture at 37 ℃ and 200rpm overnight to obtain pET26b-VioB seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(222) Adding the pET26b-VioB seed solution obtained in the step (221) into a test container containing 1L of LB liquid medium, and shake culturing in a shaking table at 37 ℃ and 200rpm until the concentration OD of the VioB expression vector is reached 600 Stop incubation at=0.8, then place the test vessel in an ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(223) Adding proper amounts of ammonium ferrous sulfate, 5-aminolevulinic acid and IPTG into the bacterial liquid treated in the step (222) respectively, so that the concentration of the ammonium ferrous sulfate in the bacterial liquid is 40 uM, the concentration of the 5-aminolevulinic acid in the bacterial liquid is 0.25 mM, and the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table for induced culture at 18 ℃ and 200rpm for 16 h;
(224) Pouring the bacterial liquid induced in the step (223) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 10% v/v glycerol, the balance being water;
(225) Crushing the bacterial body weight suspension obtained in the step (224) by using a ultrasonic crusher, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(226) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain crude VioB protein lysate.
(23) Preparation of MarC protein crude lysate
(231) Adding 10 uL of pET26b-MarC strain solution into 5 mL of LB liquid medium, and performing shake culture at 37 ℃ and 200rpm overnight to obtain pET26b-MarC seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(232) Adding the pET26b-MarC seed solution obtained in the step (231) into a test container containing 1L of LB liquid medium, and shake culturing in a shaking table at 37 ℃ and 200rpm until the concentration OD of the MarC expression vector is reached 600 Stop incubation at=1.0, then take out the test vessel and place in ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(233) Respectively adding ferrous ammonium sulfate, 5-aminolevulinic acid and IPTG into the bacterial liquid treated in the step (232) to ensure that the concentration of the ferrous ammonium sulfate in the bacterial liquid is 40 uM, the concentration of the 5-aminolevulinic acid in the bacterial liquid is 0.25 mM, and the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table for induced culture at 18 ℃ and 200rpm for 16 h;
(234) Pouring the bacterial liquid induced in the step (234) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 10% v/v glycerol, the balance being water;
(235) Crushing the bacterial body heavy suspension by using an ultrasonic crusher, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(236) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain MarC protein crude lysate;
step three: construction of enzymatic reaction System
(31) The following substances were added to the reaction vessel separately:
,
wherein:
the NaH is 2 PO 4 -Na 2 HPO 4 The concentration of the buffer solution is 1M, and the pH value is 8.0;
said (NH) 4 ) 2 SO 4 The concentration of the stock solution was 2M;
(32) After uniform mixing, vibrating and reacting for 7 hours, wherein the whole vibrating and reacting process keeps the reaction container in an open state (namely, the oxygen concentration at the upper part of the reaction container is the same as the oxygen concentration in the air);
(33) Adding 600 mL of MarC protein crude lysate prepared in the step (23), 2.1g of alpha-ketoglutaric acid, 1.32 g of ascorbic acid and a proper amount of ferrous sulfate into a reaction vessel respectively, so that the concentration of the ferrous sulfate in bacterial liquid is 0.1 mM, mixing uniformly, and continuing to shake and react for 2 hours to obtain a reaction liquid;
step four: separation and purification of the product
And (3) regulating the pH value of the reaction solution obtained in the step (III) to be 1 by using 1N dilute hydrochloric acid, adding ethyl acetate 1L to the reaction solution for extraction for at least three times, filtering an emulsion layer by using diatomite, separating the solution, combining organic phases, drying the organic phases by using anhydrous sodium sulfate, concentrating the organic phases under reduced pressure to obtain a crude product, purifying the crude product by using silica gel column chromatography, and eluting the crude product under the condition of DCM/MeOH=20:1 to obtain an orange-red product, thus obtaining the cell division inhibitor. After weighing, the weight of the cell division inhibitor was 2.65 and g, and the yield was 63.3%.
In another embodiment, after the mixing in the step (32), the shaking reaction is performed for 6 hours, and the reaction vessel is kept open during the shaking reaction.
In yet another embodiment, after the mixing in step (32), the reaction vessel is kept open during the shaking reaction for 8 hours.
1. HPLCandnuclearmagneticresonancespectroscopyanalysiswereperformedontheorange-redproductpreparedinexample1,andtheresultsareshowninFIGS.4to6,confirmingthatthefinalorange-redproductwasDDM-A.
2. theorange-redproductwasobservedunderamicroscope,andtheresultisshowninFIG.7,whereinthebar-shapedobjectinthesquareframeinFIG.7isDDM-Acrystal.
3. Determination of the IC of the orange-red product prepared in example 1 on PKC and PKA, respectively, using a Protein Kinase C (PKC) activity detection kit (PKC Kinase Activity Assay Kit) and a Protein Kinase A (PKA) activity detection kit (PKA Kinase Activity Assay Kit) 50 Values. Meanwhile, the orange-red product prepared in example 1 was examined against plasmodium falciparumPlasmodium falciparumAnd inhibitory activity of murine melanoma cell B16. The detection results obtained are as follows:
(31) Inhibition activity assay for Protein Kinase C (PKC): coating a micropore plate with a purified human PKC antibody by using a double-antibody sandwich method to prepare a solid-phase antibody, sequentially adding PKC into micropores coated with monoclonal antibodies, combining with the PKC antibody marked by HRP to form an antibody-antigen-enzyme-labeled antibody complex, and adding a substrate TMB for color development after thorough washing. TMB is converted to blue under the catalysis of HRP enzyme and to final yellow under the action of acid. Absorbance was measured with a microplate reader at a wavelength of 450nm, which correlated positively with the PKC content in the sample. The PKC concentration in the sample was calculated by a standard curve. theDDM-Asubstrateconcentrationsusedwere5uM,10uM,20uM,50uM,100uMand200uM,respectively,withareactiontimeof15minandareactiontemperatureof37℃.
(32) Inhibition activity assay for Protein Kinase A (PKA): and (3) simultaneously incubating the to-be-detected object and the TXA2 antibody marked by biotin by using an ELISA method, washing, adding the HRP marked by avidin, and adding a substrate TMB for color development after washing. Absorbance was measured with a microplate reader at a wavelength of 450nm, which correlated positively with the PKC content in the sample. The PKA concentration in the samples was calculated by standard curve. theDDM-Asubstrateconcentrationsusedwere5uM,10uM,20uM,50uM,100uMand200uM,respectively,withareactiontimeof10minandareactiontemperatureof37℃.
(33) For plasmodium falciparumPlasmodium falciparumIs determined by the inhibition activity of (a): DDM-AwasdissolvedinDMSOandassayedinmedium(5%inAlbumax II, 0.2% w/v glucose, 0.03% l-glutamine in RPMI 1640 medium) was gradient diluted and added to each well of the microtiter plate. Subsequently cultured plasmodium falciparumPlasmodium falciparumEach well was added to a final volume of 100 uL (final DMSO concentration. Ltoreq.0.25%). Plates were incubated at 37℃for 48 hours and 0.1. Mu. Ci was added to each well 3 H-hypoxanthine. The plates were mixed and incubated for an additional 24 hours. The reaction was stopped by placing the plate in a-80℃refrigerator. The cells were thawed using 96-well plates and transferred to glass fiber filter pads. Bound radioactivity was counted using a liquid Betalux scintillation counter and IC was calculated 50 Values. theDDM-Asubstrateconcentrationsusedwere1uM,2uM,5uM,10uM,20uMand50uM,respectively.
(34) Determination of inhibitory Activity on murine melanoma cell B16: 200 mousemelanomacellsB16andagradientdilutedDDM-ADMSOsolutionareaddedintotheuLreactionsystem,andthefinalconcentrationoftheDDM-Ais0.1uM,0.2uM,0.5uM,1uM,2uMand5uMrespectively. After incubation for 1h with shaking at 37deg.C, the survival of B16 cells was determined by MTT method and IC was calculated 50 Values.
Example 2
Substantially the same as in example 1, the difference is only that:
1. concentration OD of LAAD-containing expression vector in step (212) to bacterial liquid 600 Stop culturing at=1.1;
2. at step (222) up to a concentration OD of the VioB-containing expression vector 600 Stop culturing at=0.7;
3. concentration OD of MarC-containing expression vector in step (232) 600 Culture was stopped at=0.9.
Example 2 the final orange-red product gave a cell division inhibitor. After weighing, the weight of the cell division inhibitor was 2.60. 2.60 g, and the yield was 62.1%.
Example 3
Substantially the same as in example 1, the difference is only that:
1. concentration OD of LAAD-containing expression vector in step (212) to bacterial liquid 600 Stop culturing at=1.3;
2. step (a)(222) Concentration OD of medium to VioB-containing expression vector 600 Stop culturing at=0.9;
3. concentration OD of MarC-containing expression vector in step (232) 600 Culture was stopped when=1.1.
Example 2 the final orange-red product gave a cell division inhibitor. After weighing, the weight of the cell division inhibitor was 2.62. 2.62 g, and the yield was 62.6%.
The embodiments of the present invention have been described in detail. However, the present invention is not limited to the above-described embodiments, and various modifications may be made within the knowledge of those skilled in the art without departing from the spirit of the present invention.
Claims (6)
1. A method for preparing a cell division inhibitor, comprising the steps of:
step one, synthesizing key synthetase and constructing a carrier:
(11) Synthesizing LAAD gene fragments, vioB gene fragments and MarC gene fragments for expressing key synthetase, wherein:
the amino acid sequence of the LAAD gene fragment is shown as SEQ ID NO. 1;
the amino acid sequence of the VioB gene fragment is shown as SEQ ID NO. 2;
the amino acid sequence of the MarC gene fragment is shown as SEQ ID NO. 3;
(12) Cloning the LAAD gene fragment into a pET28a (+) vector by using a Gibson splicing cloning technology to obtain an expression vector pET28a (+) -LAAD, and cloning the VioB gene fragment and the MarC gene fragment into a pET26b vector to obtain an expression vector pET26b-VioB and an expression vector pET26b-MarC respectively;
(13) Respectively converting the constructed expression vectors pET28a (+) -LAAD, pET26b-VioB and pET26b-MarC into competent cells BL21 (DE 3) to obtain strain solutions, and respectively storing at-80 ℃;
step two, expressing and preprocessing key synthetase:
(21) Preparing LAAD protein crude lysate;
(22) Preparing a crude VioB protein lysate;
(23) Preparing MarC protein crude lysate;
step three, building an enzymatic reaction system:
(31) The following substances were added to the reaction vessel separately:
;
(32) After uniform mixing, carrying out oscillation reaction for 6-8h, and keeping the reaction vessel in an open state in the whole process of the oscillation reaction;
(33) Adding 600 mL of MarC protein crude lysate prepared in the step (23), 2.1g of alpha-ketoglutaric acid, 1.32 g of ascorbic acid and a proper amount of ferrous sulfate into a reaction vessel respectively, so that the concentration of the ferrous sulfate in bacterial liquid is 0.1 mM, mixing uniformly, and continuing to shake and react for 2 hours to obtain a reaction liquid;
step four, separating and purifying a product:
and (3) regulating the pH value of the reaction liquid obtained in the step (III) to be 1 by using 1N dilute hydrochloric acid, adding ethyl acetate 1L to the reaction liquid for extraction for at least three times, filtering an emulsion layer by using diatomite, separating the solution, combining organic phases, drying, concentrating under reduced pressure to obtain a crude product, purifying the crude product by using silica gel column chromatography, and eluting under the condition of DCM/MeOH=20:1 to obtain an orange-red product, thus obtaining the cell division inhibitor.
2. The method of claim 1, wherein the LAAD gene fragment, the VioB gene fragment, and the MarC gene fragment of step (12) are located between NdeI and HindIII restriction sites.
3. The method of preparing a cell division inhibitor according to claim 1, wherein the step of step (21) is as follows:
(211) Adding 10 uL of pET28a (+) -LAAD strain solution into 5 mL of LB liquid culture medium, and shaking overnight at 37 ℃ and 200rpm for culture to obtain pET28a (+) -LAAD seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(212) Adding the pET28a (+) -LAAD seed solution obtained in the step (211) into a test container containing 1L of LB liquid medium, and then shake culturing at 37 ℃ and 200rpm in a shaking table until the concentration OD of LAAD expression vector in the bacterial liquid is reached 600 Until 1.1-1.3, the test vessel was then removed and placed in an ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(213) Adding a proper amount of IPTG into the bacterial liquid treated in the step (212) to ensure that the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table to perform induction culture at 18 ℃ and 200rpm for 16 h;
(214) Pouring the bacterial liquid induced in the step (213) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 5 mM imidazole, 10% v/v glycerol, the balance being water;
(215) Crushing the bacterial body weight suspension obtained in the step (214) by using an ultrasonic crusher to obtain crushed bacterial liquid, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(216) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain LAAD protein crude lysate.
4. The method of claim 1, wherein step (22) comprises the steps of:
(221) Adding 10 uL of pET26b-VioB strain solution into 5 mL of LB liquid medium, and performing shake culture at 37 ℃ and 200rpm overnight to obtain pET26b-VioB seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(222) Adding the pET26b-VioB seed solution obtained in the step (221) into a test container containing 1L of LB liquid medium, and shake culturing in a shaking table at 37 ℃ and 200rpm until the concentration OD of the VioB expression vector is reached 600 Until =0.7-0.9, the test vessel was then placed in an ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(223) Adding proper amounts of ammonium ferrous sulfate, 5-aminolevulinic acid and IPTG into the bacterial liquid treated in the step (222) respectively, so that the concentration of the ammonium ferrous sulfate in the bacterial liquid is 40 uM, the concentration of the 5-aminolevulinic acid in the bacterial liquid is 0.25 mM, and the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table for induced culture at 18 ℃ and 200rpm for 16 h;
(224) Pouring the bacterial liquid induced in the step (223) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 10% v/v glycerol, the balance being water;
(225) Crushing the bacterial body weight suspension obtained in the step (224) by using a ultrasonic crusher, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(226) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain crude VioB protein lysate.
5. The method of preparing a cell division inhibitor according to claim 1, wherein the step of step (23) is as follows:
(231) Adding 10 uL of pET26b-MarC strain solution into 5 mL of LB liquid medium, and performing shake culture at 37 ℃ and 200rpm overnight to obtain pET26b-MarC seed solution, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(232) Adding the pET26b-MarC seed solution obtained in the step (231) into a test container containing 1L of LB liquid medium, and shake culturing in a shaking table at 37 ℃ and 200rpm until the concentration OD of the MarC expression vector is reached 600 Until =0.9-1.1, the test vessel was then removed and placed in an ice bath for 30 min, wherein:
LB liquid medium contains kanamycin with the concentration of 50 ug/mL;
(233) Respectively adding ferrous ammonium sulfate, 5-aminolevulinic acid and IPTG into the bacterial liquid treated in the step (232) to ensure that the concentration of the ferrous ammonium sulfate in the bacterial liquid is 40 uM, the concentration of the 5-aminolevulinic acid in the bacterial liquid is 0.25 mM, and the concentration of the IPTG in the bacterial liquid is 0.1 and mM, uniformly mixing, and then placing into a shaking table for induced culture at 18 ℃ and 200rpm for 16 h;
(234) Pouring the bacterial liquid induced in the step (234) into a centrifugal cup, centrifuging for 15min at 4000g, discarding the supernatant, and precipitating the surface with ddH 2 O washing followed by adding 30 mL loading buffer to suspend the precipitated bacteria to no distinct clumps to obtain a bacterial heavy suspension, wherein:
the pH value of the loading buffer solution is 8.0;
the loading buffer solution comprises: 100 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 10% v/v glycerol, the balance being water;
(235) Crushing the bacterial body heavy suspension by using an ultrasonic crusher, wherein:
the diameter of the amplitude transformer is 6 mm;
the crushing procedure is as follows: the energy is 40%, the ultrasonic circulation working time is 2 s, the suspension time is 4 s, and the total working time is 30 min;
(236) Centrifuging the crushed bacterial liquid at 10000g for 15min at low temperature, and taking supernatant to obtain MarC protein crude lysate.
6. The method of claim 1, wherein the NaH in step (31) is 2 PO 4 -Na 2 HPO 4 The concentration of the buffer solution is 1M, and the pH value is 8.0; said (NH) 4 ) 2 SO 4 The concentration of the stock solution was 2M.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310708460.9A CN116463362B (en) | 2023-06-15 | 2023-06-15 | Preparation method of cell division inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310708460.9A CN116463362B (en) | 2023-06-15 | 2023-06-15 | Preparation method of cell division inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116463362A true CN116463362A (en) | 2023-07-21 |
CN116463362B CN116463362B (en) | 2023-09-19 |
Family
ID=87181056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310708460.9A Active CN116463362B (en) | 2023-06-15 | 2023-06-15 | Preparation method of cell division inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116463362B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117384983A (en) * | 2023-12-07 | 2024-01-12 | 中国中医科学院中药研究所 | Preparation method of GSK-3 alpha inhibitor |
CN117384931A (en) * | 2023-12-06 | 2024-01-12 | 中国中医科学院中药研究所 | Preparation method of GSK-3 beta inhibitor |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030066102A1 (en) * | 1996-06-27 | 2003-04-03 | Maxwell Carl Arthur | Plant gene for p-hydroxyphenylpyruvate dioxygenase |
US20170312320A1 (en) * | 2015-05-13 | 2017-11-02 | Synlogic, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
CN107881205A (en) * | 2017-11-23 | 2018-04-06 | 中国科学院上海有机化学研究所 | The function of oxidizing ferment and its application in bicyclomycin biosynthesis |
CN108611358A (en) * | 2018-04-10 | 2018-10-02 | 佛山科学技术学院 | A method of isoniazid nicotinamide adenine dinucleotide is prepared by synthetic biology |
CN110628736A (en) * | 2019-10-09 | 2019-12-31 | 扬州大学 | Tryptophan 2,3 dioxygenase mutant and preparation method and application thereof |
CN110938580A (en) * | 2019-12-26 | 2020-03-31 | 江南大学 | Method for improving production efficiency of D-tyrosine |
CN111269900A (en) * | 2020-03-17 | 2020-06-12 | 江南大学 | Preparation and application of L-amino acid deaminase mutant |
CN111344006A (en) * | 2017-11-13 | 2020-06-26 | 奥托路斯有限公司 | Cells |
CN115992189A (en) * | 2022-11-04 | 2023-04-21 | 浙江大学 | Bacterial tryptophan-5-hydroxylase and application thereof |
-
2023
- 2023-06-15 CN CN202310708460.9A patent/CN116463362B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030066102A1 (en) * | 1996-06-27 | 2003-04-03 | Maxwell Carl Arthur | Plant gene for p-hydroxyphenylpyruvate dioxygenase |
US20170312320A1 (en) * | 2015-05-13 | 2017-11-02 | Synlogic, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
CN111344006A (en) * | 2017-11-13 | 2020-06-26 | 奥托路斯有限公司 | Cells |
CN107881205A (en) * | 2017-11-23 | 2018-04-06 | 中国科学院上海有机化学研究所 | The function of oxidizing ferment and its application in bicyclomycin biosynthesis |
CN108611358A (en) * | 2018-04-10 | 2018-10-02 | 佛山科学技术学院 | A method of isoniazid nicotinamide adenine dinucleotide is prepared by synthetic biology |
CN110628736A (en) * | 2019-10-09 | 2019-12-31 | 扬州大学 | Tryptophan 2,3 dioxygenase mutant and preparation method and application thereof |
CN110938580A (en) * | 2019-12-26 | 2020-03-31 | 江南大学 | Method for improving production efficiency of D-tyrosine |
CN111269900A (en) * | 2020-03-17 | 2020-06-12 | 江南大学 | Preparation and application of L-amino acid deaminase mutant |
CN115992189A (en) * | 2022-11-04 | 2023-04-21 | 浙江大学 | Bacterial tryptophan-5-hydroxylase and application thereof |
Non-Patent Citations (2)
Title |
---|
FANG-YUAN CHANG等: "Characterization of an Environmental DNA-Derived Gene Cluster that Encodes the Bisindolylmaleimide Methylarcyriarubin", 《CHEMBIOCHEM》, vol. 15, no. 6, pages 815 * |
KATHERINE S. RYAN等: "Divergent pathways in the biosynthesis of bisindole natural products", 《CHEM BIOL》, vol. 16, no. 4, pages 353 - 359 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117384931A (en) * | 2023-12-06 | 2024-01-12 | 中国中医科学院中药研究所 | Preparation method of GSK-3 beta inhibitor |
CN117384931B (en) * | 2023-12-06 | 2024-03-08 | 中国中医科学院中药研究所 | Preparation method of GSK-3 beta inhibitor |
CN117384983A (en) * | 2023-12-07 | 2024-01-12 | 中国中医科学院中药研究所 | Preparation method of GSK-3 alpha inhibitor |
CN117384983B (en) * | 2023-12-07 | 2024-02-23 | 中国中医科学院中药研究所 | Preparation method of GSK-3 alpha inhibitor |
Also Published As
Publication number | Publication date |
---|---|
CN116463362B (en) | 2023-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116463362B (en) | Preparation method of cell division inhibitor | |
CN101284827B (en) | Antineoplastic compounds containing triazole ring naphthoyl imines and method for preparing same | |
CN106636090A (en) | SiRNA of humanized interleukin 6, recombination expression carrier CAR-T and construction method and application of recombination expression carrier CAR-T | |
CN107422112B (en) | It is a kind of to detect the immune reagent kit of ethopabate, preparation method and application | |
CN106148256B (en) | The genetic engineering bacterium and its construction method of production alpha-arbutin and application | |
CN108203720A (en) | Her2, which can be targeted, and close PD-L1 reduces the CAR-T carriers of tumor immune escape and its construction method and application | |
CN113387892B (en) | Imidazole heterocyclic derivative containing nitrogen mustard and preparation method and application thereof | |
CN109897874A (en) | A method of preparing chiral isoquinolinecarboxylic acid | |
CN106884016A (en) | The expression vector of long-chain non-coding RNA LINC00472, tumor suppression reagent and its application | |
CN113025678A (en) | Method for screening hypoglycemic peptide capable of inhibiting alpha-amylase activity | |
CN107058418B (en) | Applications of the diterpene synthase TwCPS1 of tripterygium wilfordii two in Diterpene compound is prepared | |
CN116676295B (en) | Organic reagent-resistant beta-agarase mutant and application of immobilized enzyme | |
CN117327088A (en) | Novel chloroxanthone compound and preparation method and application thereof | |
CN108203717A (en) | Her2 can be targeted and PD-1 is interfered to reduce the CAR-T carriers of tumor immune escape and its construction method and application | |
CN109161514B (en) | Recombinant D-mannose isomerase and application thereof in D-mannose production | |
CN102432612B (en) | 4,7-dihydrotetrazole[1,5-a]pyrimidine derivative and application thereof to preparation of antitumor medicine | |
CN104910074B (en) | One class contains pyrazole derivatives of hydroxamic acid group as well as preparation method and application thereof | |
CN117384931B (en) | Preparation method of GSK-3 beta inhibitor | |
CN114773480A (en) | Antibody for resisting phosphorylation of 32 th serine residue of TOPK (TOPK) | |
CN113402357A (en) | 5-12-5 tricyclic sesterterpene skeleton compounds and preparation thereof | |
CN117384983B (en) | Preparation method of GSK-3 alpha inhibitor | |
CN108096580B (en) | Target for inhibiting neuroblastoma SH-SY5Y and application thereof | |
CN107354179A (en) | A kind of method for preparing the chipal compounds containing hydroxyl | |
CN113281313B (en) | Biological fluorescent probe for quantifying RNA output in nucleus in real time and preparation method thereof | |
CN111534495A (en) | Method for improving soluble expression of recombinant N-acetylglucosamine transferase II |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |